Preclinical and early clinical evidence demonstrates that CAR-NK cells targeting MM-associated antigens such as BCMA, GPRC5D, NKG2D, CD38, CD70, CD138, and SLAMF7 can mediate potent, selective cytotoxicity with minimal toxicity. Here, TNFRSF17 is linked to Miyoshi myopathy.